Precision Peptide orders 20,000 BPC-157 transdermal patches ahead of planned launch

  • Precision Peptide placed an order for 20,000 BPC-157 transdermal patches ahead of a planned commercial launch.
  • Initial online release targeted as early as June 2026 via the company website.
  • Each patch formulated to deliver 2 mg of BPC-157, aligned with prior third-party testing that measured 2.02 mg per patch.
  • Earlier independent lab results cited 95.5% chromatographic purity for the patch formulation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Precision Peptide Company Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202605260730NEWSFILECNPR____20260526_298787_1) on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.